Den samlede hyppighed af magliniteter blandt samtlige patienter i de individuelle studier var ens for basiliximab og comparator behandlingsgrupperne.
The overall incidence of malignancies among all patients in the individual studies was similar between the basiliximab and the comparator treatment groups.